bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.06.08.658499

Simpatico: accurate and ultra-fast virtual drug screening with atomic embeddings

Abstract

Virtual screening, the in-silico assessment of large libraries of small molecules for binding to a therapeutic protein target, is a critical early step in drug discovery. The dominant approach, molecular docking, requires a separate calculation for each protein-molecule pair, and is too slow to apply alone at the billion-compound scale of modern compound libraries. A recent embedding-retrieval paradigm, exemplified by DrugCLIP, addresses this bottleneck by training deep models to map proteins and small molecules into a shared embedding space, such that proteins are co-located with their likely binding partners; candidate ligands can then be retrieved directly by nearest-neighbors search, with no per-pair calculation. However, current embedding-retrieval methods collapse each protein and each ligand into a single embedding, creating an information bottleneck that limits the representation of partial or alternative binding compatibility. We present simpatico, an embedding-retrieval virtual screening tool that instead produces a unique embedding for each atom in a protein pocket or ligand. A CLIP-style contrastive objective trains these atomic embeddings so that protein-ligand atom pairs known to interact are nearby in embedding space. To screen a protein target, each protein-atom embedding is used as a query against a vector database of precomputed small-molecule atomic embeddings, returning the closest atoms in the library; a simple aggregation step assigns a binding score to each candidate molecule containing retrieved atoms. Where prior retrieval-based methods index one vector per ligand, simpatico indexes one per heavy atom; query time grows sublinearly in library size. On challenging decoy benchmarks, simpatico achieves state-of-the-art predictive accuracy, outperforming recent dense-retrieval methods despite training on only [~]15,000 protein-ligand complexes from PDBBind, with no pretraining and no 3D ligand pose estimation. Simpatico also exceeds the accuracy of physics-based docking and deep-learning-augmented docking methods, is competitive with diffusion-based docking, and runs orders of magnitude faster than all three. Simpatico is open source software; all code, weights, and data may be accessed at https://github.com/TravisWheelerLab/Simpatico.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Gaiser, J., Wheeler, T. J.. 2025-06-08. Simpatico: accurate and ultra-fast virtual drug screening with atomic embeddings. https://doi.org/10.1101/2025.06.08.658499

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Degradation of the TEAD-YAP/TAZ Transcription Factor Complex by Heterobifunctional Small Molecules that Bind to the TEAD Allosteric Lipid Pocket

Central kinases of the Hippo tumor suppressor pathway phosphorylate the transcriptional coactivators YAP and TAZ to sequester them in the cytoplasm. In cancer, Hippo pathway kinases have reduced activity, leading to translocation of YAP and TAZ into the nucleus where they engage TEADs and other transcription factors. Here, we explore whether heterobifunctional small molecules that bind to the TEAD allosteric lipid-binding pocket can degrade the TEAD*YAP/TAZ complex. We design and synthesize heterobifunctional molecules that consist of flufenamic acid analogs that bind to the allosteric TEAD lipid pocket, a long and flexible linker, and thalidomide to engage E3 ubiquitin ligase component cereblon. The bifunctional compounds promote ternary complex formation in biochemical assays and mammalian cells but exhibited modest degradation of TEAD, YAP, and TAZ in cancer cells. Methyl ester analogs of these compounds led to substantial proteasomal degradation of the TEAD*YAP/TAZ complex in cancer cells. This work provides a strategy for depletion of nuclear YAP and TAZ and for exploration of their TEAD-dependent and TEAD-independent activities in vivo.

pharmacology and toxicology↗